ISRG Stock Down More than 13% in 3 Months: How to Play the Stock?

Intuitive Surgical (ISRG) shares have declined 13.4% over the past three months, underperforming peers and the S&P 500, primarily due to significant gross margin contraction (200 bps in Q2, 200-300 bps projected for FY2025) driven by higher costs, product mix shifts, and potential tariffs. This margin pressure, coupled with increasing competition from Medtronic and J&J, international budget constraints, and moderating bariatric procedures due to GLP-1 drugs, is weighing on earnings despite the company's leading market position, strong procedure growth (2025 guidance raised to 15.5-17%), and high recurring revenue. The stock is considered overvalued, suggesting continued near-term earnings pressure and volatility despite its long-term market leadership in robotic surgery.

Analysis

Intuitive Surgical (ISRG) is facing a significant disconnect between its strong top-line growth and deteriorating profitability, leading to recent share price underperformance of -13.4% over three months against gains in the broader market and key competitors. The primary headwind is a severe contraction in gross margin, which fell approximately 200 basis points year-over-year in the second quarter and is forecast to contract by 200-300 bps for the full year 2025. This pressure stems from higher costs, the launch of the new da Vinci 5 system, product mix shifts, and an anticipated 100 bps impact from tariffs. Consequently, while sales are projected to grow, earnings are expected to decelerate, with forecasted growth of only 8.7% in Q3 and a decline of 1.8% in Q4. These margin concerns overshadow positive fundamental drivers, including a dominant market position, raised full-year procedure growth guidance to 15.5-17%, and a robust recurring revenue model that accounts for 85% of total sales. However, additional risks are compounding, including moderating bariatric procedure volumes due to the rise of GLP-1 drugs, increasing competition from lower-cost systems by Medtronic and Johnson & Johnson, and international budget constraints limiting system adoption. The stock's premium valuation, with a forward P/E of 50.56X versus the sector's 27.51X, combined with weak technicals trading below its 50-day and 200-day moving averages, suggests near-term risks are not fully priced in.

Key Decisions for Investors

• Investors should weigh the company's strong top-line drivers, including market leadership and raised procedure growth guidance of 15.5-17%, against the significant near-term pressure on profitability from a projected 200-300 bps annual gross margin contraction.
• Given the stock's premium valuation at a 50.56X forward P/E and weak technical posture, it may be prudent to await evidence of margin stabilization or a more attractive entry point before initiating new long positions.
• Closely monitor key risks including the market penetration of competing systems from Medtronic and Johnson & Johnson, the sustained impact of GLP-1 drugs on bariatric surgery volumes, and any further margin erosion from potential escalations in U.S.-China tariffs.